TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00093236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Periodontal Treatment
Description: Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Dental Hygiene
Description: Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
Study: NCT00116454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 131 I-lipiodol
Description: intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
Study: NCT03906266

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: NRS 2002, nutric, SGA and adductor pollicis
Description: NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: NRS 2002, nutric, SGA and adductor pollicis
Description: NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: NRS 2002, nutric, SGA and adductor pollicis
Description: NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NRS 2002, nutric, SGA and adductor pollicis
Description: NRS 2002, nutric, SGA and adductor pollicis tests detects the malnutrition
Study: NCT03114033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted therapeutic mild hypercapnia
Description: Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted normocapnia (Standard care)
Description: Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change \>5 mmHg.
Study: NCT04557644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saarbrucken Personality questionnaire (SPQ) addressing empathy.
Description: Empathy is additionally assessed by the Saarbrucken Personality Questionnaire (SPQ) ,a 16-item tool.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 10-items-questionnaire addressing previous dermatological conditions, intensity of itch
Description: 10-items-questionnaire (completed by the hospitalised family) regarding demographic information (gender, age, profession), previous dermatological conditions, intensity of itch a.) on the first day of the hospitalisation, b.) when seeing the skin lesions of the other family members c.) when talking about the scabies/itch with the other family members, d.) when seeing other family members scratching themselves, and questions regarding their intensity of disgust of the scabies and empathy for the other family members (0-10 NRS).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ItchyQol-questionnaire composed of 22 items addressing itch-related symptoms, functions and emotions
Description: ItchyQol-questionnaire to assess the itch-related quality of life impairment. The ItchyQoL is composed of 22 items addressing itch-related symptoms, functions and emotions.
Study: NCT03535688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: 200 mg twice daily
Study: NCT01379625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triheptanoin
Description: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triheptanoin
Description: Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
Study: NCT04748263

Intervention type: OTHER
Intervention: No intervention. Only survey and normal use of eye-tracking
Description: The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE.

Intervention type: OTHER
Intervention: No intervention. Only survey and normal use of eye-tracking
Description: The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE.

Intervention type: OTHER
Intervention: No intervention. Only survey and normal use of eye-tracking
Description: The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE.

Intervention type: OTHER
Intervention: No intervention. Only survey and normal use of eye-tracking
Description: The study is conducted in accordance with usual practices of eye-tracking and neuropsychological evaluations carried out at the Center Rainier III.~Eye-Tracker® is used at the Centre Rainier III since August 2014. It is a non-invasive device for eye movements recording, allowing doctors and researchers to measure standard parameters related to eye movements. Developed by the Eye Brain Company (France), this is a Class IIa medical device, CE marking, according to Annexe IX of the directive 93/42/CE.
Study: NCT03535688

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily
Study: NCT01178021

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine/Primaquine
Description: Chloroquine 10 mg/kg on day 0 \& 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
Study: NCT05247411

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: During the videoconference, the following items were investigated and evaluated:~(i) Knowledge on FM: knowledge on symptoms, onset, treatment, strategies and non-pharmacological interventions that can be implemented to improve the quality of life (physical exercise, nutrition, participation in meditative movement practices, mutual aid groups, membership in a patient association, etc.); (ii) Any MC intake or interest in starting the intake of MC; (iii) Knowledge on MC therapy: specific knowledge on the drug, correct intake, adherence, treatment of side effects related to intake and strategies to reduce them; (iv) Self-care: how the person manages his personal life despite a chronic disease, how she or he monitors, recognizes and treats the symptoms in terms of timing and quality; possible presence of caregivers in their life who help in the management of the disease; employment and how FM affects it and daily life.
Study: NCT04179903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical Activity program is performed in a group in a gym and at home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: Physical Activity program is performed in a group in a gym and at home
Study: NCT04475328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AngongNiuhuang pill
Description: This group will receive AngongNiuhuang pill 1pill qd/day for 5-day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AngongNiuhuang pill
Description: This group will receive placebo of AngongNiuhuang pill 1pill qd/day for 5-day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard treatment
Description: The other treatments according to guidelines for standard treatment of acute ischemic stroke
Study: NCT02748343

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: allograft bone
Description: Use of the allograft bone to treat the bone defect in patients

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tissue-engineered bone
Description: Use of the tissue-engineered bone to treat the bone defect in patients
Study: NCT04442607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence image processing
Description: Patients will undergo a standard colonoscopy performed by a trained endoscopist. A second observer, who is not a trained endoscopist, will follow the procedure on a bedside AI-tool to count the number of detections made by the AI system and categorize the results into positive or negative results as follows (1) true positive, (2) false negative or (3) false positive.
Study: NCT03139292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSeal Laryngeal Mask Airway
Description: ProSeal Laryngeal Mask Airway was used as the supraglottic device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmbuAuraGain Laryngeal Mask Airway
Description: AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
Study: NCT00743236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: warm ischemia procedure
Description: Warm ischemia followed by partial nephrectomy
Study: NCT04590248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.
Study: NCT03077867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus floor augmentation with bone graft
Description: sinus floor augmentation with lateral approach with bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor augmentation with bone graft
Description: sinus floor augmentation with lateral approach with bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor augmentation with bone graft
Description: sinus floor augmentation with lateral approach with bone graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus floor augmentation with bone graft
Description: sinus floor augmentation with lateral approach with bone graft
Study: NCT02617251

Intervention type: OTHER
Intervention: No intervention
Study: NCT03469076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YUN ACN Cream
Description: YUN ACN Cream with live probiotic bacteria (min. 10-6 à 10-7 CFU per application) applied twice daily (morning and evening) on the entire face
Study: NCT04435340

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Selective Sonography of the ventral abdominal hernia level
Description: The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Selective Sonography of the ventral abdominal hernia level
Description: The primary outcome of the study is measured by an radiologist experienced in abdominal ultrasound with a linear ultrasound transducer (ML 6-15 Hz). In case of aggravated examination circumstances a different ultrasound transducer is used (linear 9 L or convex C 1-6 Hz)
Study: NCT03152292

Intervention type: OTHER
Intervention: Real-world, non-interventional
Description: N/A - non-interventional

Intervention type: OTHER
Intervention: Real-world, non-interventional
Description: N/A - non-interventional

Intervention type: OTHER
Intervention: Real-world, non-interventional
Description: N/A - non-interventional
Study: NCT00744289

Intervention type: OTHER
Group type: OTHER
Intervention: Incentive condition
Description: Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
Study: NCT03822910

Intervention type: DIAGNOSTIC_TEST
Intervention: Pattern Separation Paradigm
Description: Will be used to investigate dentate gyrus (DG) and hippocampal CA3 subfield as reflected by the difference in brain activation in response to same as previously seen (OLD) vs similar to previously seen (SIM) objects in first episode (FEP) subjects before and after treatment.
Study: NCT04601454

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation System
Description: Rechargeable Implanted neurostimulation system (neurostimulator and leads) with on-label stimulation parameters.
Study: NCT03603366

Intervention type: DRUG
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.

Intervention type: DRUG
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: This study does not involve prescription of the drugs. This study is a cross-sectional survey of patients taking low-dose aspirin or patients who are eligible but not taking low-dose aspirin.
Study: NCT02634476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol approach/avoidance task
Description: The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham approach/avoidance task
Description: The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
Study: NCT02605044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib (AB1010)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FOLFIRI
Study: NCT03532607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Patients will listen to soothing music for 30 minutes before their standard of care botox injection
Study: NCT03584529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 3
Description: Non-Vitamin D3 Drops group Patients in this group would take nothing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D 3
Description: Non-Vitamin D3 Drops group Patients in this group would take nothing.
Study: NCT01095094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir
Description: Given orally
Study: NCT00280111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 116E AGMK
Description: Single dose of 116E 10\^5 FFu

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I321
Description: Single dose of I321 10\^5 FFu

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
Study: NCT01027390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training exercise
Description: physical exercise training at the work site during work time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training exercise
Description: physical exercise training at the work site during work time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training exercise
Description: physical exercise training at the work site during work time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical training exercise
Description: physical exercise training at the work site during work time
Study: NCT03725254

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lymphadenectomy
Description: The retroperitoneal lymphadenectomy includes all lymph, fat, and connective tissue in the retroperitoneal space.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chemoradiotherapy
Description: Radiation therapy is highly appropriate, based on the characteristics of the lesion and the surrounding critical organs, and select IMRT or stereotactic radiotherapy (SBRT).
Study: NCT01518738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breath attention training
Description: 4 week training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: working memory attention training
Description: 4 week training
Study: NCT05905614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336 Tablets
Description: Open-label SPH4336 Tablets ：Administered by oral
Study: NCT03841981

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonographic studies
Description: * Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonographic studies
Description: * Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonographic studies
Description: * Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: Sonographic studies
Description: * Polycystic ovarian morphology.~* Carotid intima-media thickness.~* Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory blood pressure monitoring
Description: A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory blood pressure monitoring
Description: A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory blood pressure monitoring
Description: A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory blood pressure monitoring
Description: A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Intervention type: DIAGNOSTIC_TEST
Intervention: 24-hour Ambulatory blood pressure monitoring
Description: A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

Intervention type: PROCEDURE
Intervention: Percutaneous biopsy
Description: Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Intervention type: PROCEDURE
Intervention: Percutaneous biopsy
Description: Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

Intervention type: PROCEDURE
Intervention: Percutaneous biopsy
Description: Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.
Study: NCT01886560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
Study: NCT03822910

Intervention type: DIAGNOSTIC_TEST
Intervention: Sequential Associative Mismatch Paradigm
Description: used to reflect activation of CA1 in response to mismatching information compared to memory of the stimulus in FEP subjects before and after antipsychotic treatment and in matched Healthy Control (HC).